Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Financings In Brief

This article was originally published in The Gray Sheet

Executive Summary

Aradigm/Novo Nordisk: Restructured licensing agreement with Novo Nordisk concerning Aradigm's AERx pulmonary drug delivery system for diabetes management results in a $55 mil. payment to Aradigm, minus previous advances. Under the Jan. 26 deal, Novo Nordisk gains assets, building leases and employees associated with AERx, which is in clinical trials (1"The Gray Sheet" Jan. 3, 2005, p. 17). Aradigm retains AERx' intellectual property and will receive royalties on sales. The move dovetails with President & CEO Bryan Lawlis' plan to focus on advancing Aradigm's needle-free Intraject system for treating migraine headaches...

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts